NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.
The 2021 Inc.5000 ranks companies by overall revenue growth over a three-year period, from 2017 to 2020. ObvioHealth grew by more than 1200 percent in that timeframe. The average three-year growth rate for all companies on the list was 543 percent.
Since its inception in 2017, the startup has conducted more than 40 decentralized clinical trials for clients in the pharmaceutical, biotechnology, medical device and consumer health sectors. In February, ObvioHealth launched its next generation platform with enhanced remote patient monitoring capabilities which integrate FDA-cleared devices that can monitor up to 20 clinical grade vital signs. Most recently, ObvioHealth raised $31 million in its latest round of financing and secured two major partners extending its expertise in real world data and its geographic footprint in APAC.
“Our commitment to innovating in the clinical research industry has proven to be both strategic and prescient as the pandemic makes accessing traditional trials more difficult,” said Ivan Jarry, CEO of ObvioHealth. “Our ranking on this prestigious list is a testament to that commitment. We are poised for another year of significant growth and look forward to making the clinical trial process even more efficient for both sponsors and patients.”
ObvioHealth welcomes sales veteran Richard Watkins as CRO to guide the company’s shift to enterprise software. His proven leadership in SaaS and healthcare will help expand ObvioGo® 2.0’s impact on clinical trials worldwide.
ObvioHealth announces the appointment of seasoned healthcare executive Nicholas Campbell to its Board of Directors. Campbell brings expertise to accelerate digital innovation and advance clinical trial solutions.